Astellas Pharma Inc (4503.T)
5,340JPY
1 Aug 2013
¥90 (+1.71%)
¥5,650
¥5,340
¥5,440
¥5,270
1,584,600
2,037,500
¥6,010
¥3,715
About
Overall
| Beta: | 0.60 |
| Market Cap (Mil.): | ¥2,399,064.00 |
| Shares Outstanding (Mil.): | 456.96 |
| Dividend: | 65.00 |
| Yield (%): | 2.48 |
Financials
| 4503.T | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 29.26 | 37.93 | 37.76 |
| EPS (TTM): | 179.42 | -- | -- |
| ROI: | 7.47 | 19.48 | 18.76 |
| ROE: | 7.97 | 20.17 | 19.59 |
UPDATE 1-China probes pricing at drugmakers including GSK, Merck
* Top agency to review costs, prices at dozens of drugmakers
Deals of the day -- mergers and acquisitions
(Updates Kabel Deutschland; Adds Siemens, PPR, Dell, Astellas Pharma, Nokia, Lekoil, Nordea, Chevron)
Exclusive: Japan's Astellas looks to sell dermatology assets - sources
NEW YORK - Japanese drugmaker Astellas Pharma Inc is looking to sell its dermatology portfolio, which could be worth between $500 million and $1 billion, according to three people familiar with the situation.
Amgen to make move into Japan, takes on Astellas as partner
- Amgen Inc, the world's largest biotechnology company, said it entered into a long-term collaboration with Astellas Pharma Inc and will form a joint venture with the Japanese drugmaker to provide new medicines in Japan.
Amgen to make move into Japan, takes on Astellas as partner
* Sees first commercial launch of new drug in Japan in 2016
Basilea antifungal wins coveted U.S. orphan drug status
ZURICH, May 28 - Swiss biotech group Basilea has won coveted orphan drug status from U.S. health authorities for antifungal treatment isavuconazole, the company said on Tuesday.
Aveo says partner Astellas will not seek EU nod for kidney cancer drug
- Aveo Pharmaceuticals Inc said it was informed by its partner Astellas Pharma Inc that the Japanese company would not be seeking marketing approval for their experimental kidney cancer drug in Europe.
EU body backs new Roche, Astellas, Sanofi, Vivus drugs
LONDON - European regulators have recommended approval of two new cancer drugs, called Erivedge and Xtandi, from Roche and Astellas, underscoring a recent pick-up in novel treatments for the disease.
UPDATE 1-EU body backs new Roche, Astellas, Sanofi, Vivus drugs
LONDON, April 26 - European regulators have recommended approval of two new cancer drugs, called Erivedge and Xtandi, from Roche and Astellas, underscoring a recent pick-up in novel treatments for the disease.
EU agency backs new Roche, Astellas, Sanofi, Vivus drugs
LONDON, April 26 - European regulators have recommended approval of two new cancer drugs, called Erivedge and Xtandi, from Roche and Astellas.
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: Datamonitor
|
$175.00
|
|
Provider: GlobalData
|
$250.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

